Product Description

Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) is a key member of the tumor necrosis factor (TNF) superfamily, known for its critical role in regulating cell differentiation, proliferation, and survival. RANKL exists as a type II homotrimeric transmembrane protein and can be found in both membrane-bound and soluble forms. RANKL specifically binds to its receptor, RANK (Receptor Activator of Nuclear Factor Kappa-B), to initiate downstream signaling pathways, including the AKT pathway, which governs cell survival and function. The decoy receptor osteoprotegerin (OPG) also interacts with RANKL, competitively inhibiting its binding to RANK and thereby modulating RANKL activity. Functionally, RANKL plays a central role in osteoclast differentiation and activation, contributing to bone remodeling and resorption. Beyond the skeletal system, RANKL also participates in immune regulation, including T cell activation and broader immune signaling processes. ORF Biologics’ recombinant RANKL is produced to deliver high purity, biological activity, and batch-to-batch consistency, making it ideal for research applications in bone metabolism, immune cell regulation, and TNF superfamily signaling.

Product Application

• Osteoclast Differentiation – Induces osteoclast formation and activity from precursor cells in vitro
• Bone Metabolism Research – Supports studies of bone remodeling, osteoporosis, and related disorders
• Immune Regulation – Enables investigation of RANKL-mediated T cell activation and dendritic cell survival

Format: Lyophilized

Product Specifications

Product Description

Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) is a key member of the tumor necrosis factor (TNF) superfamily, known for its critical role in regulating cell differentiation, proliferation, and survival. RANKL exists as a type II homotrimeric transmembrane protein and can be found in both membrane-bound and soluble forms. RANKL specifically binds to its receptor, RANK (Receptor Activator of Nuclear Factor Kappa-B), to initiate downstream signaling pathways, including the AKT pathway, which governs cell survival and function. The decoy receptor osteoprotegerin (OPG) also interacts with RANKL, competitively inhibiting its binding to RANK and thereby modulating RANKL activity. Functionally, RANKL plays a central role in osteoclast differentiation and activation, contributing to bone remodeling and resorption. Beyond the skeletal system, RANKL also participates in immune regulation, including T cell activation and broader immune signaling processes. ORF Biologics’ recombinant RANKL is produced to deliver high purity, biological activity, and batch-to-batch consistency, making it ideal for research applications in bone metabolism, immune cell regulation, and TNF superfamily signaling.

Product Application

• Osteoclast Differentiation – Induces osteoclast formation and activity from precursor cells in vitro
• Bone Metabolism Research – Supports studies of bone remodeling, osteoporosis, and related disorders
• Immune Regulation – Enables investigation of RANKL-mediated T cell activation and dendritic cell survival

Format: Lyophilized

Product Specifications